Voyager Therapeutics Inc (VYGR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Voyager Therapeutics Inc (VYGR) has a cash flow conversion efficiency ratio of -0.141x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.05 Million) by net assets ($219.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Voyager Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Voyager Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Voyager Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Voyager Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Voyager Therapeutics Inc ranked by their cash flow conversion efficiency. Explore VYGR operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shane Global Holding Inc
TW:8482
|
0.060x |
|
Westwood Holdings Group Inc
NYSE:WHG
|
-0.020x |
|
Tianjin Capital Environmental Protection Group Company Limited
F:TIA
|
0.070x |
|
Neto M.E Holdings Ltd
TA:NTO
|
0.088x |
|
Ilex Medical
TA:ILX
|
0.070x |
|
Auden Techno
TW:3138
|
0.013x |
|
China ZhengTong Auto Services Holdings Limited
F:ZA0
|
-0.141x |
|
Calin Technology Co Ltd
TW:4976
|
-0.039x |
Annual Cash Flow Conversion Efficiency for Voyager Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Voyager Therapeutics Inc from 2013 to 2024. View VYGR live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $299.76 Million | $-15.31 Million | -0.051x | -115.49% |
| 2023-12-31 | $236.32 Million | $77.92 Million | 0.330x | +255.57% |
| 2022-12-31 | $59.02 Million | $-12.51 Million | -0.212x | +62.36% |
| 2021-12-31 | $95.06 Million | $-53.52 Million | -0.563x | +10.15% |
| 2020-12-31 | $154.32 Million | $-96.72 Million | -0.627x | -228.15% |
| 2019-12-31 | $99.51 Million | $48.67 Million | 0.489x | +242.97% |
| 2018-12-31 | $46.45 Million | $-15.89 Million | -0.342x | +25.26% |
| 2017-12-31 | $134.05 Million | $-61.35 Million | -0.458x | -46.43% |
| 2016-12-31 | $135.92 Million | $-42.48 Million | -0.313x | -227.95% |
| 2015-12-31 | $169.07 Million | $41.30 Million | 0.244x | +102.35% |
| 2014-12-31 | $1.15 Million | $-11.92 Million | -10.372x | -829.50% |
| 2013-12-31 | $-3.83 Million | $-5.45 Million | 1.422x | -- |
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more